Replimune (REPL) Jumps As FDA Panel Backs Melanoma Drug

Replimune Group Inc. stocks have been trading up by 128.65 percent amid highly positive sentiment on its latest oncology progress

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading REPL

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

FDA advisers voted 10–3 that RP1 plus nivolumab shows clinically meaningful benefit in advanced melanoma, backing data from Replimune’s single‑arm IGNYTE study.
The Cellular, Tissue, and Gene Therapies Advisory Committee said the RP1 efficacy results are evaluable, supporting Replimune Group Inc.’s BLA resubmission.
A Prescription Drug User Fee Act (PDUFA) decision date is set for 2026/08/02, giving traders a clear regulatory catalyst for REPL.
Wedbush remains Neutral on REPL with a $9 target, citing FDA trial‑design concerns and limited confidence in near‑term approval despite the bullish advisory vote.

Live Update At 07:47:30 EDT: On Friday, July 31, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending up by 128.65%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

REPL is trading like a classic biotech volatility story. Just days ago, Replimune Group Inc. closed at $9.87, then slid to $8.63, before collapsing to $5.35 and $5.41 as traders repriced risk around the FDA meeting. That’s a brutal drawdown from above $11 earlier in the month, showing how tightly REPL trades around headlines instead of fundamentals.

Intraday action tells the same story. In the latest premarket tape, REPL whipped from about $10.86 at the open to over $13 before settling in the low‑$12s. Those wide 5‑minute candles show aggressive momentum trading, with both longs and shorts battling around the FDA panel news.

More Breaking News

On the fundamentals, Replimune is still a clinical‑stage biotech burning cash. The latest quarter shows a net loss of about $73.2M and negative EBITDA, with heavy research and development spend near $52.3M. REPL’s operating cash flow was roughly -$56.2M for the quarter, but the company ended with about $209.0M in cash and $268.9M in cash plus short‑term investments. For traders, that runway and the strong liquidity ratios mean dilution or financing risk is real but not immediate. The stock trades around 2.7x book value, signaling that the market still assigns meaningful optionality to RP1’s future.

Why Traders Are Zeroed In On REPL Now

REPL is front and center on biotech screens because the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee just handed the company a major win. The panel voted 10–3 that the efficacy data from Replimune’s IGNYTE trial of RP1 plus nivolumab in advanced melanoma is both “evaluable” and “clinically meaningful.” For a single‑arm study, that’s huge. The core fear was whether the FDA would even take the dataset seriously. This vote says yes.

Replimune Group Inc. is aiming to resubmit its Biologics License Application for RP1, and the Food and Drug Administration has already set a PDUFA date of 2026/08/02. That timestamp now becomes a focal point for REPL trading. Panel support doesn’t guarantee approval, but historically it boosts expectations and narrows the range of outcomes traders are willing to price in.

The market loves clarity. Before this week, REPL had a dark cloud over it: a single‑arm trial design, questions about how much benefit comes from RP1 versus the nivolumab backbone, and a regulator viewed as skeptical. With the 10–3 vote, Replimune has partially cleared that hurdle. The committee explicitly said the IGNYTE results are solid enough to judge and clinically meaningful for advanced melanoma patients.

Still, not everyone is jumping on the bull side. Wedbush had flagged ahead of the meeting that it expected the committee to see the RP1 data as meaningful, yet the firm kept a Neutral rating and a $9 price target. Their stance lines up with traders who see the advisory vote as a de‑risking event but not a done deal. They’re still worried about the FDA’s broader negative tone on trial design and component contribution.

That tension is exactly what creates opportunity. REPL is now trading between fear of a future FDA pushback and optimism that the strong advisory vote nudges RP1 toward approval. For active traders, this is textbook: a defined catalyst ahead, clear levels on the chart, and a story everyone on the Street is watching.

Conclusion

For REPL, the latest FDA advisory vote is a classic turning point. Replimune Group Inc. now has formal backing that its RP1 plus nivolumab data in advanced melanoma is both analyzable and clinically meaningful. That removes one of the biggest overhangs on the story: the idea that a single‑arm IGNYTE trial would get tossed aside by regulators. Instead, the panel endorsed it 10–3 and supported the ongoing BLA resubmission toward the 2026/08/02 PDUFA date.

Yet REPL is not a straight‑line story from here. Replimune is still losing more than $70M a quarter, and the business depends on turning RP1 into a real commercial product. The Wedbush Neutral rating and $9 target are a reminder that some on the Street doubt the timing and certainty of approval, even with this strong panel outcome. That mixed backdrop is why the chart has been so wild, with REPL swinging from the $11s down into the mid‑$5s in a matter of days.

For traders, this is exactly the type of setup Tim Sykes talks about: a catalyst‑driven stock where you “ride the momentum, but always be ready to cut losses fast.” It also echoes the pattern‑recognition focus that many day trading educators emphasize; as Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” REPL now has a clear regulatory path, a defined date, and massive crowd attention. The opportunity is real, but so is the risk. As always, this analysis is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!